RELIATech - angiogenesis, lymphangiogenesis, cytokines, antibodies, VEGF-A, PlGF, VEGF-C, Prox-1, LYVE-1, Podoplanin, KDR, flt-1, flt-4, VEGF-C ELISA, HGF, BMP-2, FGF-2, blood vessel, lymph vessel, angiogenic growth factors, neovascularisation

	Cytokine Reagents / Human

	Cytokine Reagents / Murine - Rat

	Soluble Receptors

	ELISA-Kits

	Monoclonal Antibodies

	Polyclonal Antibodies

	Specialities

	Functional Antibodies "Angio-Proteomie"

	Control IgGs

Customer Services

New Products

Product of the Month

Angiogenesis Products

	Company Profile

	Jobs@ReliaTech

	Studienarbeiten

	General Terms

	Bank Account

	Find us

	Imprint


	Receptor Ligand Technologies GmbH

	Lindenerstr. 15 38300 Wolfenbüttel Germany

	Tel: +49 (0)5331 8586 987 Fax: +49 (0)5331 8586 989

	eMail: info@reliatech.de

Anti-human soluble VEGFR-2/KDR

Anti-human soluble VEGFR-1/Flt-1

Focus on.......

NEW Anti-human VE-Statin/EGFL-7 (cat# 102-PA14S/-14) raised in rabbits are now available! (Mapping /IHC/IHC2)	NEW Discrimination between soluble and transmembrane Flt-1 by a specific polyclonal antibody (IHC, Cat# 102-PA21S )
NEW Two novel monoclonal antibodies that distinguish mouse lymphatic (LEC) and blood vascular (BEC) endothelial cells NOW AVAILABLE! (Ezaki et al, 2006; Buttler et al., 2008)	NEW Anti-human PlGF monoclonal antibody from mouse are now available! (IHC with Cryo sections; Immunofluorescence)
Anti-mouse/-human VEGF-A antibodies for IHC with paraffin-embedded sections cross reacting with human tissue. (#103-PA03S; #103-PA03AG; #101-M58) Pretreatment: 0.01% Proteinase K, 15min, RT	IHC with anti-human TIE-2 monoclonal antibodies on cryo-sections (Figure)
Anti-human CD105/Endoglin (Cat# 102-PA60) Staining of colon carcinoma tissue (Fig.1) and FACS analysis with mouse C57B16 cells (Fig.2).	Anti-human LYVE-1 "Biotin" (#102-PABi50) and anti-human TIE-1 Cl. 6F12 "Biotin" (#101-MBi48) are now available for direct FACS analysis!
New monoclonal antibodies against human VEGFR-2 anti-human VEGFR-2, Clone 3 and Clone 4 (Cat# 101-M32 / 101-M34).	New monoclonal antibodies against human TIE-1 anti-human TIE-1 Clone 8C9 and 6F12 (Cat# 101-M46/ -M48)

New monoclonal antibodies against human TIE-2/tek
anti-human TIE-2/tek, Clone 2, 9 and 16
(Cat# 101-M50/ -M52/ -M54).

Anti-Prox-1
a polyclonal antibody suitable for immunofluorescence staining of frozen sections (Cat# 102-PA32S)
(see also New Products!)

FACS analysis with antibodies against Podoplanin (#101-M40) and LYVE-1 (#102-PA50)
with human microvascular endothelial cells.

New Monoclonal Antibodies!

The following monoclonal antibodies will be NOW available:

1. Mouse anti-human Podoplanin #4D5aE5E6
2. Mouse anti-rat Podoplanin #LF3(B7)D5B3
3. Mouse anti-rat Aminopeptidase P #JG12C9C10
4. Mouse anti-human Podocalyxin #GB6D9C11
5. Mouse anti-human Megalin #CD7D5

EU Consortium

RELIATech is a new member of the EU Consortium for Lymphangiogenomics

Since September 2007 RELIATech GmbH located in Braunschweig, North Germany, is the 14th member in the Europe-wide EU consortium „Lymphangiogenomics“ an integraded project of the “Sixth Framework Programme for Life Sciences, Genomics, and Biotechnology for Health”. Its aim is to thoroughly dissect the processes of lymphangiogenesis and to compare them with angiogenesis at the genetic, molecular, cellular, and functional level. The consortium started in 2004, is coordinated by Professor Kari Alitalo from Helsinki and was granted 9 M€. New findings and discoveries in this innovative research field should mainly lead to the development of new pharmaceuticals for the inhibition of tumor metastasis and for treatment of inflammatory and cardiovascular diseases.

For more information see: http://www.lymphomic.org/

Recombinant Protein Expression in Mammalian Cells!

RELIATech is now offering a new service contract production of animal cell cultures in a bioreactor scale.

This includes:

Recombinant protein production with mammalian cell lines such as CHO, BHK21 and HEK 293
Monoclonal antibody production with hybridomas (etc.)
Production of cell mass (e.g. HeLa for preparation of nuclear extracts, etc.)
Recombinant protein production with insect cell culture and the Baculovirus Expression System

Facility:

The cell culture fermentation facility is equipped with stirred-tank bioreactors which can be operated in batch, fed-batch, or continous perfusion mode for the cultivation of both suspension cells and anchorage-dependent cells (microcarrier culture).

RELIATech bietet nun auch einen neuen Service für die Auftragsproduktion tierischer Zellkulturen im Bioreaktor-Maßstab an.

Dieser beinhaltet:

Rekombinante Proteinproduktion mit Säugerzelllinien wie CHO, BHK21 und HEK 293
Produktion monoklonaler Antikörper mit Hybridomazelllinien (etc.)
Produktion von Zellmasse (z.B. HeLa für die Herstellung von Kernextrakten, etc.)
Rekombinante Proteinproduktion mit Insektenzellkulturen und dem Baculovirus Expressionssystem

Anlage:

Die Zellkulturfermentationsanlage ist mit Rührkessel-Bioreaktoren ausgestattet, die im Batch, Fed-Batch oder kontinuierlichen Perfusionsmodus betrieben werden können. Sie sind sowohl für die Kultivierung von Suspensionszellen als auch für adhärente Zellen (Microcarrier-Kultur) einsetzbar.

Antibodies for lymphatic endothelial cells!

Cellular markers and isolation of lymphatic ECs: new possibilities for well known proteins!

A Minireview! (More)

CD31
LYVE-1
CD31 / LYVE-1

The experiments were perfomed by Dr. Ulrike Fiedler and Stefanie Koidel, Dept. of Vascular Biology and Angiogenesis Research
Tumor Biology Center, Breisacher Str. 117, D-79106 Freiburg, Germany

Recombinant Protein Expression

Customer Services: From GENE to PROTEIN!

RELIATech offers a full customer service for the expression of recombinant proteins in insect cells (Baculovirus) and E. coli. These services are divided into a series of steps which can be performed either individually or in combination so that you can select the steps you actually need. These services are designed to adequately cover most of your needs, from gene cloning into a Baculovirus transfer vector or an E. coli expression vector, the generation of recombinant baculovirus or E. coli strain, up to the production and purification of recombinant protein. If desired we also will try to establish a assay for determining the biological activity of the purified protein.

Antibodies for vascular endothelial cells!

VEGF receptors – key mediators of vascular formation and lymphangiogenesis

A Minireview! (More)

PEDF, a natural angiogenesis inhibitor!

PEDF, a natural angiogenesis inhibitor!

The EPC-1 (early population doubling level cDNA-1) gene, also known as pigment epithelium-derived factor, encodes a protein belonging to the serine protease inhibitor (serpin) superfamily that has been reported to inhibit angiogenesis and proliferation of several cell types.

Blood vessel growth and stability are under the exquisite control of a network of pro- and anti-angiogenic factors. Disruption of the balance between these factors is a characteristic of tumor growth and many vascular diseases. Endogenous angiogenesis inhibitors, particularly those that act broadly at the earliest stages, could be excellent pharmacological tools in combating pathogenic vessel growth. Pigment-epithelium-derived factor (PEDF) [PDF.] is a natural angiogenesis inhibitor that (1) targets only new vessel growth, (2) can be administered therapeutically as a soluble protein or by viral-mediated gene transfer, (3) is stable and nontoxic when injected, and (4) is more potent than other well-characterized angiogenesis inhibitors. Because PEDF also has differentiating and neuroprotective activities, it has additional benefits for use in the nervous system. The production of PEDF by many tissues suggests its therapeutic potential should be explored in a much wider range of diseases, including tumor proliferation and metastasis.

sVEGFR-1/sFlt-1: the exclusive Factor for Preeclampsia?

Risk from Placenta: the exclusive Factor for Preeclampsia discovered?

Preeclampsia is still a very severe disease during pregnancy. The disease affected about 5% of pregnant women, about 15% of all maternal deaths are related to this disease. Up to know there is now causative treatment, - with the exception to abort pregnancy. Scientists from the Beth Israel Hospital from Boston have now identified the putative factor responsible for the disease. As recently published in the “Journal of Clinical Investigations” (Vol. 111, p. 649) it seems to be the soluble receptor protein sFlt1 (sVEGFR-1).

Click here for more information

SHOPPING CART

Your order »

Pricelist

Link to the
German DFG Priority Grand
"The TUMOR-VESSEL INTERFACE"
SPP 1190